Cat. No.: HY-N0112

Dihydromyricetin

(Synonyms: Ampelopsin; Ampeloptin)

26 Cited Publications

Avis client

Based on 26 publication(s) in Google Scholar

Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.73%
CAS No.: 27200-12-0
Formule: C₁₅H₁₂O₈
Masse moléculaire:320.25

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Dihydromyricetin Chemical Structure

CAS No.: 27200-12-0

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (26)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]^[3]

RNA Polymerase

Dihydropyrimidinase

48 μM (IC₅₀)

mTORC1

mTORC2

Autophagy

Voir tous les produits spécifiques à Isoform mTOR :

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>10 μM Compound: 13	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BT-549	IC₅₀	>10 μM Compound: 13	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BV-2	IC₅₀	32.66 μM Compound: 13	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay	[PMID: 28165740]
RAW264.7	IC₅₀	6.25 μg/mL Compound: 115	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced COX-2 expression after 24 hrs by Western blot analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced COX-2 expression after 24 hrs by Western blot analysis	[PMID: 37683361]
RAW264.7	IC₅₀	6.25 μg/mL Compound: 115	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced iNOS expression after 24 hrs by Western blot analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced iNOS expression after 24 hrs by Western blot analysis	[PMID: 37683361]
SK-MEL-2	IC₅₀	>10 μM Compound: 13	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 28165740]
SK-OV-3	IC₅₀	>10 μM Compound: 13	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 28165740]
Vero C1008	CC₅₀	>200 μM Compound: 88	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay	[PMID: 37597436]

In Vitro

Dihydromyricetin, a flavonol, significantly inhibits the catalytic activities of dihydropyrimidinase toward both the natural substrate dihydrouracil and xenobiotic substrate 5-propyl-hydantoin. Dihydromyricetin exhibits a significant inhibitory effect on the activities of dihydropyrimidinase for both substrates, even more than Myricetin does. The IC₅₀ values of Dihydromyricetin for dihydropyrimidinase determined from the titration curves using Dihydrouracil and 5-propyl-hydantoin are 48±2 and 40±2 μM, respectively^[1].
Dihydromyricetin (DHM) supplementation significantly reverses the increased phosphorylation of mTOR at Ser²⁴⁴⁸ (p-mTOR) during D-gal administration, which suggests that Dihydromyricetin can activate autophagy through inhibiting mTOR signaling^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Changes in learning and memory capacity in rats administrated normal control group, D-gal group, D-gal+Dihydromyricetin (100 mg/kg) group, D-gal+Dihydromyricetin (200 mg/kg) group assessed by morris water maze (MWM) (n=10 per group). Dihydromyricetin (DHM) treatment significantly shortens the escape latency when compared with D-gal-induced model group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 27200-12-0
Appearance Solid
Masse moléculaire 320.25
Formule C₁₅H₁₂O₈
Color White to off-white
SMILES

O=C1[C@H](O)[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
Synonyms

Ampelopsin; Ampeloptin
Structure Classification
- Flavonoids
- Flavanonols
- Phenols
- Polyphenols
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (26)

All Histological Imaging/StainingWBIFRT-PCR

Sort by:

Journal Impact Factor

Metabolism

Hepatocyte DDIT4 aggravates MASH progression through GPX4-mediated ferroptosis. [Abstract]

2026 Jul:180:156622. PMID: 41997496
Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186
Mol Ther

MicroRNA-34a Promotes Renal Fibrosis by Downregulation of Klotho in Tubular Epithelial Cells. [Abstract]

2019 May 8;27(5):1051-1065. PMID: 30853453

Dihydromyricetin purchased from MedChemExpress. Usage Cited in: Mol Ther. 2019 May 8;27(5):1051-1065. [Abstract]

DHM (500 mg/kg/day) was suspended in 0.9% saline and intragastrically administered to C57BL/6J mice 7 days before UUO surgery and continued until the end of the experiment. Representative micrographs of H&E and Masson trichrome staining of mouse kidney sections at 14 days after UUO surgery were shown.

Dihydromyricetin purchased from MedChemExpress. Usage Cited in: Mol Ther. 2019 May 8;27(5):1051-1065. [Abstract]

DHM (500 mg/kg/day) was suspended in 0.9% saline and intragastrically administered to C57BL/6J mice 7 days before UUO surgery and continued until the end of the experiment. Western blotting analysis was performed to assess E-cadherin, $\alpha$-SMA, and fibronectin protein levels in UUO mice at 14 days after surgery.

Dihydromyricetin purchased from MedChemExpress. Usage Cited in: Mol Ther. 2019 May 8;27(5):1051-1065. [Abstract]

Representative immunostaining of E-cadherin, $\alpha$-SMA, and fibronectin in the obstructed kidneys at 14 days after UUO surgery. E-cadherin (green), fibronectin (red), and DAPI (blue) were shown. The scale bars corresponded to 50 μm. DHM (500 mg/kg/day) was suspended in 0.9% saline and intragastrically administered to C57BL/6J mice 7 days before UUO surgery and continued until the end of the experiment.

Dihydromyricetin purchased from MedChemExpress. Usage Cited in: Mol Ther. 2019 May 8;27(5):1051-1065. [Abstract]

qRT-PCR analysis of miR-34a expression in HK-2 cells pretreated with different concentrations of DHM for 24 h followed by incubation with 10 ng/mL TGF-β1 for 24 or 48 h.

Dihydromyricetin purchased from MedChemExpress. Usage Cited in: Mol Ther. 2019 May 8;27(5):1051-1065. [Abstract]

Western blotting analysis of Klotho in HK-2 cells pretreated with DHM (100 mM) for 24 h followed by incubation with 10 ng/mL TGF-β1 for 48 h.
Phytomedicine

Dihydromyricetin confers cerebroprotection against subarachnoid hemorrhage via the Nrf2-dependent Prx2 signaling cascade. [Abstract]

2023 Jul 26;119:154997. PMID: 37523836
Phytomedicine

Dihydromyricetin attenuates intracerebral hemorrhage by reversing the effect of LCN2 via the system Xc- pathway. [Abstract]

2023 Jul:115:154756. PMID: 37130481
Phytomedicine

Dihydromyricetin protects against Doxorubicin-induced cardiotoxicity through activation of AMPK/mTOR pathway. [Abstract]

2022 May:99:154027. PMID: 35278898
Mater Today Bio

Orchestrating diabetic wound repair via mitochondria-targeted delivery of dihydromyricetin with tailored ADSC-derived biohybrid nanovesicles. [Abstract]

2026 Feb 16:37:102934. PMID: 41756529
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 Oct 15:489:144992. PMID: 40466530
Clin Sci

Dihydromyricetin ameliorates vascular calcification in chronic kidney disease by targeting AKT signaling. [Abstract]

2021 Nov 12;135(21):2483-2502. PMID: 34643227
Eur J Med Chem

Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. [Abstract]

2020 Dec 15:208:112754. PMID: 32883638
Biochem Pharmacol

Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1. [Abstract]

2020 May:175:113888. PMID: 32112883
Ind Crops Prod

2025 Dec 11;239:122458.
Eur J Pharmacol

Dihydromyricetin restores mucus hypersecretion in Air-Liquid interface cultures in COPD by targeting the SRC-MAPK signaling pathway. [Abstract]

2025 Aug 5:1000:177703. PMID: 40348325
Eur J Pharmacol

Dihydromyricetin attenuates intervertebral disc degeneration by inhibiting NLRP3 inflammasome activation via the Keap1/Nrf2/HO-1 pathway. [Abstract]

2025 Jul 5:998:177501. PMID: 40058758
Int J Mol Sci

Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade. [Abstract]

2026 Feb 5;27(3):1576. PMID: 41683994
Front Pharmacol

CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]

2020 Nov 11:11:580407. PMID: 33343350
Philos Trans R Soc Lond B Biol Sci

Small molecule activates citrullination through targeting PAD2. [Abstract]

2023 Nov 20;378(1890):20220248. PMID: 37778388
Food Sci Nutr

Dihydromyricetin regulates KEAP1-Nrf2 pathways to enhance the survival of ischemic flap. [Abstract]

2024 Feb 20;12(6):3893-3909. PMID: 38873488
Cardiovasc Toxicol

Dihydromyricetin Protects Against Hypoxia/Reoxygenation Injury in Cardiomyocytes by Activating miR-34a-Mediated Notch1 Pathway. [Abstract]

2025 Feb;25(2):294-305. PMID: 39864044
Exp Eye Res

Dihydromyricetin mitigates oxidative damage induced by mixed phthalates via Nrf2 activation in experimental models of glaucoma. [Abstract]

2026 Feb:263:110761. PMID: 41270819
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Clin Exp Pharmacol Physiol

Dihydromyricetin protects sevoflurane-induced mitochondrial dysfunction in HT22 hippocampal cells. [Abstract]

2024 Sep;51(9):e13912. PMID: 39103220
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
SSRN

2026 May 3.
Biomed Pharmacother

Berbamine promotes ferroptosis of esophageal squamous cell carcinoma by facilitating USP51-mediated GPX4 ubiquitination and degradation. [Abstract]

2024 Oct:179:117309. PMID: 39151312

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (312.26 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1226 mL

15.6128 mL

31.2256 mL

5 mM

0.6245 mL

3.1226 mL

6.2451 mL

10 mM

0.3123 mL

1.5613 mL

3.1226 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[1]

A rapid spectrophotometric assay is used to determine the enzymatic activity for hydantoinase, allantoinase, dihydroorotase, and imidase. Dihydrouracil, 5-propyl-hydantoin, and phthalimide are used as substrates. Unless explicitly stated otherwise, Dihydrouracil (2 mM) is used as the substrate in the standard assay of dihydropyrimidinase. Briefly, the decrease in absorbancy at 230, 248, and 298 nm is measured upon hydrolysis of Dihydrouracil, 5-propyl-hydantoin, and Phthalimide as the substrate at 25°C, respectively. To start the reaction, the purified dihydropyrimidinase (10-70 μg) is added to a 2 mL solution containing the substrate and 100 mM Tris-HCl (pH 8.0). Substrate hydrolysis is monitored with a UV/vis spectrophotometer. The extinction coefficient of each substrate is determined experimentally by direct measurement with a spectrophotometer. The extinction coefficients of Dihydrouracil, 5-propyl-hydantoin, and Phthalimide are 0.683 mM^-1cm^-1 at 230 nm, 0.0538 mM^-1cm^-1 at 248 nm, and 3.12 mM^-1cm^-1 at 298 nm, respectively. The initial rates of change are a function of enzyme concentration within the absorbance range of 0.01-0.18 min^-1. A unit of activity is defined as the amount of enzyme catalyzing the hydrolysis of 1 μmol substrate/min, and the specific activity is expressed in terms of units of activity per milligram of enzyme. The kinetic parameters K_m and V_max are determined from a non-linear plot by fitting the hydrolyzing rate from individual experiments to the Michaelis-Menten equation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

Hippocampus and cortex tissue samples are homogenized in lysis buffer containing 20 mM Tris (pH 7.5), 135 mM NaCl, 2 mM EDTA, 2 mM DTT, 25 mM β-glycerophosphate, 2 mM sodium pyrophosphate, 10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 10 mM NaF, 10 μg/mL aprotinin, 10 μg/mL leupeptin, and 1 mM PMSF for 30 min on ice and centrifuged at 12000×g at 4°C for 30 min. The supernatant is collected and protein quantification is carried out using a BCA kit. The protein samples are boiled in the presence of sample buffer at 95°C for 5 min. The target protein is separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membrane, and then probed by corresponding primary and secondary antibodies. Finally, the target protein is visualized by enhanced chemiluminescence (ECL) reagent exposure to X-ray film^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Rats^[2]
Totally 40 male Sprague-Dawley (SD) rats (age: 8 weeks old; body weight: 160±20 g) are used. The rats are randomly divided into four groups including normal control group, D-gal model group, and D-gal combined with DHM at the doses of 100 and 200 mg/kg-d groups with 10 rats in each group. All rats are housed at the environment with room temperature of 22±2°C and a dark-light cycle (12 h: 12h), and provided the accessibility to food and water ad libitum. After adapting to new environment for 1 week, the rats from DHM groups are administered with DHM dissolved in distilled water at the designated dosages by gavage once a day at 8:00am for 6 consecutive weeks. The rats from the normal control group are administrated with distilled water. Except from the normal control group, the rats from other groups are subjected to subcutaneous injection of D-gal at the dose of 150 mg/kg.d for 6 consecutive weeks. Each administration of DHM should be 2 h ahead of D-gal injection.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Huang CY. Inhibition of a Putative Dihydropyrimidinase from Pseudomonas aeruginosa PAO1 by Flavonoids and Substrates of Cyclic Amidohydrolases. PLoS One. 2015 May 19;10(5):e0127634. [Content Brief]

[2]. Chang H, et al. Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway. Carcinogenesis. 2014 Aug;35(8):1847-54. [Content Brief]

[3]. Kou X, et al. Ampelopsin attenuates brain aging of D-gal-induced rats through miR-34a-mediated SIRT1/mTORsignal pathway. Oncotarget. 2016 Nov 15;7(46):74484-74495. [Content Brief]

[4]. Václav Zima, et al. Unraveling the Anti-Influenza Effect of Flavonoids: Experimental Validation of Luteolin and its Congeners as Potent Influenza Endonuclease Inhibitors. Eur J Med Chem. 22 August 2020, 112754.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1226 mL	15.6128 mL	31.2256 mL	78.0640 mL
	5 mM	0.6245 mL	3.1226 mL	6.2451 mL	15.6128 mL
	10 mM	0.3123 mL	1.5613 mL	3.1226 mL	7.8064 mL
	15 mM	0.2082 mL	1.0409 mL	2.0817 mL	5.2043 mL
	20 mM	0.1561 mL	0.7806 mL	1.5613 mL	3.9032 mL
	25 mM	0.1249 mL	0.6245 mL	1.2490 mL	3.1226 mL
	30 mM	0.1041 mL	0.5204 mL	1.0409 mL	2.6021 mL
	40 mM	0.0781 mL	0.3903 mL	0.7806 mL	1.9516 mL
	50 mM	0.0625 mL	0.3123 mL	0.6245 mL	1.5613 mL
	60 mM	0.0520 mL	0.2602 mL	0.5204 mL	1.3011 mL
	80 mM	0.0390 mL	0.1952 mL	0.3903 mL	0.9758 mL
	100 mM	0.0312 mL	0.1561 mL	0.3123 mL	0.7806 mL

Keywords

Dihydromyricetin

26 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Dihydromyricetin

Myricetin

Chlorogenic acid

Baicalein

Taxifolin

Isorhamnetin

Eriodictyol

Naringenin

Luteolin

Quercetin